251 related articles for article (PubMed ID: 36892023)
21. Application and development of noninvasive biomarkers for colorectal cancer screening: a systematic review.
Song D; Wang F; Ju Y; He Q; Sun T; Deng W; Ding R; Zhang C; Xu Q; Qi C; Bao J
Int J Surg; 2023 Apr; 109(4):925-935. PubMed ID: 36974713
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
Das V; Kalita J; Pal M
Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
[TBL] [Abstract][Full Text] [Related]
23. Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.
Hallermayr A; Wohlfrom T; Steinke-Lange V; Benet-Pagès A; Scharf F; Heitzer E; Mansmann U; Haberl C; de Wit M; Vogelsang H; Rentsch M; Holinski-Feder E; Pickl JMA
J Hematol Oncol; 2022 Sep; 15(1):125. PubMed ID: 36056434
[TBL] [Abstract][Full Text] [Related]
24. Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer.
Wang JJ; Wang X; Song YX; Zhao JH; Sun JX; Shi JX; Wu ZH; Wang ZN
Dis Markers; 2019; 2019():2587109. PubMed ID: 31275444
[TBL] [Abstract][Full Text] [Related]
25. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of Circulating Tumor Cells in Prognosis of Stage III/IV Colorectal Cancer After Oxaliplatin-based First-line Chemotherapy.
Yu J; Zhang J; Peng T; Fei Z; Jin L; Yang M
In Vivo; 2022; 36(2):806-813. PubMed ID: 35241536
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver.
Kaifi JT; Kunkel M; Dicker DT; Joude J; Allen JE; Das A; Zhu J; Yang Z; Sarwani NE; Li G; Staveley-O'Carroll KF; El-Deiry WS
Cancer Biol Ther; 2015; 16(5):690-8. PubMed ID: 25785486
[TBL] [Abstract][Full Text] [Related]
28. Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment.
Yao S; Han Y; Yang M; Jin K; Lan H
Front Immunol; 2023; 14():1292861. PubMed ID: 38077354
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
30. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction.
Nassar FJ; Msheik ZS; Nasr RR; Temraz SN
Clin Epigenetics; 2021 May; 13(1):111. PubMed ID: 34001239
[TBL] [Abstract][Full Text] [Related]
31. Circulating lncRNA UCA1 and lncRNA PGM5-AS1 act as potential diagnostic biomarkers for early-stage colorectal cancer.
Wang M; Zhang Z; Pan D; Xin Z; Bu F; Zhang Y; Tian Q; Feng X
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212174
[TBL] [Abstract][Full Text] [Related]
32. Molecular biomarkers in the diagnostic of patients with colorectal cancer.
Fabišíková K; Behulová RL; Repiska V
Neuro Endocrinol Lett; 2019 Dec; 40(5):215-221. PubMed ID: 32112545
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer.
Abdalla TSA; Meiners J; Riethdorf S; König A; Melling N; Gorges T; Karstens KF; Izbicki JR; Pantel K; Reeh M
PLoS One; 2021; 16(6):e0252897. PubMed ID: 34111181
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor cell enumeration for improved screening and disease detection of patients with colorectal cancer.
Tsai WS; Hung WS; Wang TM; Liu H; Yang CY; Wu SM; Hsu HL; Hsiao YC; Tsai HJ; Tseng CP
Biomed J; 2021 Dec; 44(6 Suppl 2):S190-S200. PubMed ID: 35292267
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Circulating Tumor Cells in Colorectal Cancer as an Adjunctive Non-invasive Diagnostic Method.
Nursyirwan SA; Abdullah M; Sulaiman AS; Rinaldi I; Makmun D; Simadibrata M; Noor DR; Wiraatmadja A; Jeo WS; Rahadiani N; Handjari DR; Shatri H
Acta Med Indones; 2023 Oct; 55(4):385-395. PubMed ID: 38213054
[TBL] [Abstract][Full Text] [Related]
36. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer.
Pan X; Zhang X
Future Oncol; 2020 Jun; 16(18):1289-1299. PubMed ID: 32379501
[No Abstract] [Full Text] [Related]
37. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
38. The potential of liquid biopsy in the management of cancer patients.
Markou A; Tzanikou E; Lianidou E
Semin Cancer Biol; 2022 Sep; 84():69-79. PubMed ID: 35331850
[TBL] [Abstract][Full Text] [Related]
39. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer.
Imaoka H; Toiyama Y; Fujikawa H; Hiro J; Saigusa S; Tanaka K; Inoue Y; Mohri Y; Mori T; Kato T; Toden S; Goel A; Kusunoki M
Ann Oncol; 2016 Oct; 27(10):1879-86. PubMed ID: 27502702
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor cells in colorectal cancer in the era of precision medicine.
Hu M; Wang Z; Wu Z; Ding P; Pei R; Wang Q; Xing C
J Mol Med (Berl); 2022 Feb; 100(2):197-213. PubMed ID: 34802071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
